Stemcells, Inc. Expands SC Proven® Product Portfolio with Launch of Proprietary Human Cell Detection Antibodies
Product News Dec 07, 2010
These high potency antibodies are the latest additions to the Company’s growing SC Proven® portfolio of research products, and provide powerful, cost-effective tools for the detection, tracking and characterization of human cells both in vitro and when transplanted into animal models of human diseases.
“The commercial launch of these proprietary antibodies demonstrates our ongoing commitment to broaden our portfolio of innovative research products and to take advantage of the growing market for research-grade cells, media and reagents,” said Stewart Craig, Senior Vice President, Development and Operations at StemCells, Inc. “Their utility has been proven by our scientists and by independent academic collaborators in the conduct of their research and development activities. These antibodies have also become the cornerstone of our extensive preclinical studies, which have allowed us to successfully advance our stem cell therapeutic candidates into multiple clinical trials. There is considerable demand for these reagents, so we are pleased to now make them available to the scientific community at large.”
STEM101, STEM121 and STEM123 are human-specific mouse monoclonal antibodies that have been extensively used to detect the engraftment, migration and differentiation of human neural stem cells and human liver engrafting cells (hLEC™) transplanted into rodents.1,2,3,4,5 These antibodies can be used for immunohistochemistry and immunofluorescence applications such as:
• Quantifying the location and number of engrafted cells
• Tracking the migration pattern of engrafted cells
• Determining the nature of engrafted cells
• Identifying specific differentiated human-derived cells such as astrocytes
STEM101 recognizes the Ku80 protein found in human nuclei, STEM121 recognizes a cytoplasmic protein of human cells, and STEM123 recognizes human glial fibrillary acidic protein (GFAP).